Marker Historical Balance Sheet

MRKR Stock

USD 3.26 0.07 2.10%

Trend analysis of Marker Therapeutics balance sheet accounts such as Total Current Liabilities of 4.6 M provides information on Marker Therapeutics' total assets, liabilities, and equity, which is the actual value of Marker Therapeutics to its prevalent stockholders. By breaking down trends over time using Marker Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Marker Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Marker Therapeutics is a good buy for the upcoming year.

Marker Therapeutics Inventory

(844,848)

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.

About Marker Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Marker Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Marker Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Marker Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Marker currently owns. An asset can also be divided into two categories, current and non-current.

Marker Therapeutics Balance Sheet Chart

At this time, Marker Therapeutics' Other Current Assets are relatively stable compared to the past year. As of 11/27/2024, Other Stockholder Equity is likely to grow to about 472.8 M, while Total Stockholder Equity is likely to drop slightly above 7.1 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Marker Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Marker Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Marker Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Marker Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Marker Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Marker Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.At this time, Marker Therapeutics' Other Current Assets are relatively stable compared to the past year. As of 11/27/2024, Other Stockholder Equity is likely to grow to about 472.8 M, while Total Stockholder Equity is likely to drop slightly above 7.1 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	11.9M	7.6M	8.8M	9.2M
Total Assets	68.1M	34.4M	17.1M	13.6M

Short Long Term Debt Total Total Assets

Marker Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Non Currrent Assets Other	Property Plant Equipment
Total Assets		0.49	-0.04	0.07	0.93	0.48	-0.81	-0.72	0.69	0.92	0.65	0.92	0.19	-0.05	0.54	0.55	-0.45	0.67	0.75	0.36	0.5	0.95	-0.13	0.06	-0.18	0.34
Short Long Term Debt Total	0.49		-0.03	0.14	0.34	0.97	-0.06	-0.74	0.68	0.21	0.76	0.21	0.59	0.19	0.81	0.7	-0.27	0.88	0.73	0.49	0.97	0.27	0.28	0.04	-0.72	0.82
Other Current Liab	-0.04	-0.03		0.94	-0.34	-0.01	0.07	0.02	0.07	-0.06	0.04	-0.06	-0.02	0.23	-0.06	0.03	-0.18	-0.02	-0.06	0.76	-0.01	-0.06	-0.13	0.24	0.06	-0.01
Total Current Liabilities	0.07	0.14	0.94		-0.27	0.1	0.08	-0.04	0.31	-0.02	0.23	-0.02	0.01	0.44	0.01	0.28	-0.22	0.13	0.0	0.89	0.11	-0.01	0.15	0.47	0.06	0.07
Total Stockholder Equity	0.93	0.34	-0.34	-0.27		0.34	-0.88	-0.66	0.49	0.94	0.44	0.94	0.12	-0.19	0.47	0.34	-0.36	0.54	0.71	0.0	0.36	0.95	-0.21	-0.1	-0.13	0.26
Property Plant And Equipment Net	0.48	0.97	-0.01	0.1	0.34		-0.1	-0.83	0.56	0.22	0.69	0.22	0.68	0.02	0.91	0.55	-0.29	0.91	0.81	0.42	1.0	0.27	0.08	-0.18	-0.78	0.91
Net Debt	-0.81	-0.06	0.07	0.08	-0.88	-0.1		0.54	-0.32	-0.97	-0.09	-0.97	0.11	0.12	-0.31	0.0	0.38	-0.3	-0.59	0.02	-0.12	-0.95	0.29	0.03	-0.1	-0.1
Retained Earnings	-0.72	-0.74	0.02	-0.04	-0.66	-0.83	0.54		-0.44	-0.59	-0.55	-0.59	-0.65	0.07	-0.94	-0.35	0.56	-0.86	-1.0	-0.29	-0.83	-0.64	0.16	0.28	0.67	-0.81
Accounts Payable	0.69	0.68	0.07	0.31	0.49	0.56	-0.32	-0.44		0.49	0.76	0.49	-0.02	0.21	0.39	0.82	-0.25	0.67	0.45	0.62	0.6	0.52	0.3	0.43	-0.06	0.37
Cash	0.92	0.21	-0.06	-0.02	0.94	0.22	-0.97	-0.59	0.49		0.31	1.0	-0.04	-0.07	0.36	0.24	-0.41	0.43	0.64	0.14	0.24	1.0	-0.21	0.06	0.03	0.15
Non Current Assets Total	0.65	0.76	0.04	0.23	0.44	0.69	-0.09	-0.55	0.76	0.31		0.31	0.47	0.02	0.52	0.93	-0.27	0.77	0.53	0.65	0.71	0.37	0.1	0.09	-0.45	0.46
Cash And Short Term Investments	0.92	0.21	-0.06	-0.02	0.94	0.22	-0.97	-0.59	0.49	1.0	0.31		-0.04	-0.07	0.36	0.24	-0.41	0.43	0.64	0.14	0.24	1.0	-0.21	0.06	0.03	0.15
Net Receivables	0.19	0.59	-0.02	0.01	0.12	0.68	0.11	-0.65	-0.02	-0.04	0.47	-0.04		0.02	0.71	0.29	-0.27	0.56	0.62	0.21	0.65	0.02	-0.04	-0.39	-0.87	0.69
Common Stock Total Equity	-0.05	0.19	0.23	0.44	-0.19	0.02	0.12	0.07	0.21	-0.07	0.02	-0.07	0.02		-0.03	0.28	-0.03	0.01	-0.09	0.35	0.02	-0.06	0.87	0.85	-0.02	0.02
Common Stock Shares Outstanding	0.54	0.81	-0.06	0.01	0.47	0.91	-0.31	-0.94	0.39	0.36	0.52	0.36	0.71	-0.03		0.31	-0.37	0.91	0.93	0.26	0.91	0.41	-0.03	-0.3	-0.7	0.95
Non Current Liabilities Total	0.55	0.7	0.03	0.28	0.34	0.55	0.0	-0.35	0.82	0.24	0.93	0.24	0.29	0.28	0.31		-0.21	0.6	0.34	0.66	0.58	0.29	0.38	0.4	-0.32	0.28
Inventory	-0.45	-0.27	-0.18	-0.22	-0.36	-0.29	0.38	0.56	-0.25	-0.41	-0.27	-0.41	-0.27	-0.03	-0.37	-0.21		-0.35	-0.55	-0.3	-0.29	-0.43	0.11	0.01	0.23	-0.25
Other Current Assets	0.67	0.88	-0.02	0.13	0.54	0.91	-0.3	-0.86	0.67	0.43	0.77	0.43	0.56	0.01	0.91	0.6	-0.35		0.85	0.47	0.92	0.48	0.05	-0.09	-0.56	0.85
Other Stockholder Equity	0.75	0.73	-0.06	0.0	0.71	0.81	-0.59	-1.0	0.45	0.64	0.53	0.64	0.62	-0.09	0.93	0.34	-0.55	0.85		0.25	0.81	0.68	-0.16	-0.28	-0.64	0.79
Total Liab	0.36	0.49	0.76	0.89	0.0	0.42	0.02	-0.29	0.62	0.14	0.65	0.14	0.21	0.35	0.26	0.66	-0.3	0.47	0.25		0.44	0.17	0.17	0.42	-0.18	0.28
Property Plant And Equipment Gross	0.5	0.97	-0.01	0.11	0.36	1.0	-0.12	-0.83	0.6	0.24	0.71	0.24	0.65	0.02	0.91	0.58	-0.29	0.92	0.81	0.44		0.29	0.09	-0.16	-0.74	0.91
Total Current Assets	0.95	0.27	-0.06	-0.01	0.95	0.27	-0.95	-0.64	0.52	1.0	0.37	1.0	0.02	-0.06	0.41	0.29	-0.43	0.48	0.68	0.17	0.29		-0.2	0.05	-0.02	0.2
Short Term Debt	-0.13	0.28	-0.13	0.15	-0.21	0.08	0.29	0.16	0.3	-0.21	0.1	-0.21	-0.04	0.87	-0.03	0.38	0.11	0.05	-0.16	0.17	0.09	-0.2		0.8	0.02	0.06
Common Stock	0.06	0.04	0.24	0.47	-0.1	-0.18	0.03	0.28	0.43	0.06	0.09	0.06	-0.39	0.85	-0.3	0.4	0.01	-0.09	-0.28	0.42	-0.16	0.05	0.8		0.36	-0.27
Non Currrent Assets Other	-0.18	-0.72	0.06	0.06	-0.13	-0.78	-0.1	0.67	-0.06	0.03	-0.45	0.03	-0.87	-0.02	-0.7	-0.32	0.23	-0.56	-0.64	-0.18	-0.74	-0.02	0.02	0.36		-0.66
Property Plant Equipment	0.34	0.82	-0.01	0.07	0.26	0.91	-0.1	-0.81	0.37	0.15	0.46	0.15	0.69	0.02	0.95	0.28	-0.25	0.85	0.79	0.28	0.91	0.2	0.06	-0.27	-0.66

Click cells to compare fundamentals

Marker Therapeutics Account Relationship Matchups

Marker Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	46.4M	45.6M	68.1M	34.4M	17.1M	13.6M
Other Current Liab	30.7K	2.7M	5.4M	3.6M	1.9M	2.5M
Total Current Liabilities	2.0M	6.4M	12.9M	7.8M	3.1M	4.6M
Total Stockholder Equity	44.1M	27.3M	44.0M	19.6M	14.1M	7.1M
Property Plant And Equipment Net	873.2K	21.2M	22.2M	17.8M	20.5M	21.5M
Net Debt	(43.4M)	(9.1M)	(30.5M)	(4.2M)	(15.1M)	(14.4M)
Retained Earnings	(327.5M)	(356.2M)	(398.1M)	(428.0M)	(436.3M)	(414.5M)
Accounts Payable	993K	2.9M	5.1M	1.1M	961K	1.3M
Cash	43.9M	21.4M	42.4M	11.8M	15.1M	9.6M
Cash And Short Term Investments	43.9M	21.4M	42.4M	11.8M	15.1M	9.6M
Net Receivables	56.2K	1.0M	237.0	2.4M	1.0M	1.1M
Common Stock Total Equity	10.6K	45.4K	45.7K	50.7K	58.3K	41.4K
Common Stock Shares Outstanding	4.6M	4.7M	7.7M	8.4M	8.8M	9.2M
Liabilities And Stockholders Equity	46.4M	45.6M	68.1M	34.4M	17.1M	13.6M
Non Current Liabilities Total	1.6M	280.2K	11.9M	11.2M	7.0M	0.0
Other Current Assets	1.5M	2.1M	3.6M	2.4M	2.0M	2.1M
Other Stockholder Equity	371.6M	383.5M	442.0M	447.6M	450.3M	472.8M
Total Liab	2.3M	18.3M	24.1M	14.8M	3.1M	6.0M
Property Plant And Equipment Gross	873.2K	21.2M	24.9M	17.8M	20.5M	21.5M
Total Current Assets	45.5M	24.4M	46.0M	16.6M	17.1M	10.3M
Short Term Debt	204.1K	777.6K	1.2M	577.2K	663.8K	714.4K
Common Stock	45.7K	50.7K	83.1K	8.4K	8.9K	8.4K
Non Currrent Assets Other	(472.0)	(21.2M)	2.2M	(17.8M)	(16.0M)	(15.2M)
Net Tangible Assets	59.3M	44.1M	27.3M	44.0M	50.6M	53.1M
Capital Surpluse	161.1M	365.4M	371.6M	383.5M	441.1M	230.6M
Net Invested Capital	44.1M	27.3M	44.0M	19.6M	14.1M	24.2M
Net Working Capital	43.5M	18.0M	33.1M	8.8M	14.1M	20.6M
Capital Stock	45.7K	50.7K	83.1K	8.4K	8.9K	8.4K

Pair Trading with Marker Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Marker Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marker Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Marker Stock

0.5	MNOV	MediciNova	Pair Corr
0.45	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.39	FDMT	4D Molecular Therapeutics	Pair Corr
0.35	NKTX	Nkarta Inc Buyout Trend	Pair Corr

The ability to find closely correlated positions to Marker Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Marker Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Marker Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Marker Therapeutics to buy it.

The correlation of Marker Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Marker Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Marker Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Marker Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Marker Stock Analysis

When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Marker Historical Balance Sheet

Marker Therapeutics Inventory

(844,848)

About Marker Balance Sheet Analysis

Marker Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Marker Therapeutics balance sheet Correlations

Marker Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Marker Therapeutics balance sheet Accounts

Pair Trading with Marker Therapeutics

Moving against Marker Stock

Additional Tools for Marker Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Net	+ 0.97	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.97	Short Long Term Debt Total

Other Stockholder Equity	- 1.0	Retained Earnings
Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Total Current Assets	- 0.95	Net Debt
Common Stock Shares Outstanding	- 0.94	Retained Earnings
Net Debt	- 0.88	Total Stockholder Equity